Showing results (71-80 of 2,397) with videos related to
Sort By:
Pageof 240
Translational Lung Cancer Research|January 25, 2021
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle wonFabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, et al.Translational Lung Cancer Research|January 25, 2021
Decade in review: a new era for RET-rearranged lung cancersNoura J Choudhury, Alexander DrilonTranslational Lung Cancer Research|January 25, 2021
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategiesAlessandro Russo, Andrés F Cardona, Christian Caglevic, et al.Translational Lung Cancer Research|January 25, 2021
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapyKenichi Suda, Tetsuya MitsudomiTranslational Lung Cancer Research|January 25, 2021
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged diseaseLorenza Landi, Federico CappuzzoTranslational Lung Cancer Research|February 11, 2021
Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Women's Health InitiativeDongfang You, Mingzhi Zhang, Wenjing He, et al.Translational Lung Cancer Research|February 11, 2021
Prognostic significance of cribriform adenocarcinoma of the lung: validation analysis of 1,057 Japanese patients with resected lung adenocarcinoma and a review of the literatureNaoki Nakajima, Akihiko Yoshizawa, Mariyo Rokutan-Kurata, et al.Translational Lung Cancer Research|February 11, 2021
Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective studyVincent Bourbonne, Alice Delafoy, François Lucia, et al.Translational Lung Cancer Research|February 11, 2021
Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutationsRyo Ko, Takehito Shukuya, Chiyo K Imamura, et al.Translational Lung Cancer Research|February 11, 2021
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefitYusuke Tomita, Bryan Oronsky, Nacer Abrouk, et al.Pageof 240